Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update

On August 30, 2024, Relief Therapeutics Holding SA announced its half-year financial results, highlighting several key developments. The company anticipates results from the RLF-TD011 trial for epidermolysis bullosa wound treatment in the coming weeks and notable progress in the RLF-OD032 pilot study, with a potential NDA filing by mid-2025.

Significant financial improvements were reported for the first half of 2024. Revenue increased by 85%, while operating expenses decreased by 45%, owing to strategic realignment. Stable R&D investments have helped maintain the company's forward momentum.

The company's cash reserves of CHF 15.1 million as of August 30, 2024, are expected to fund operations at least through 2026. Relief Therapeutics remains debt-free and optimistic about its strategic initiatives and development programs.